Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$83.09 USD

83.09
657,361

+4.91 (6.28%)

Updated Oct 4, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (182 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Why HealthEquity (HQY) Could Beat Earnings Estimates Again

by Zacks Equity Research

HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Reasons to Add Patterson Companies (PDCO) in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Down -8.48% in 4 Weeks, Here's Why You Should You Buy the Dip in HealthEquity (HQY)

by Zacks Equity Research

HealthEquity (HQY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ELV vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. HQY: Which Stock Is the Better Value Option?

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall

by Zacks Equity Research

Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.

Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

by Zacks Equity Research

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

by Zacks Equity Research

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip

by Zacks Equity Research

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

PacBio's (PACB) New Offering to Boost WGS Data Analysis

by Zacks Equity Research

PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.

3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

ELV vs. HQY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELV vs. HQY: Which Stock Is the Better Value Option?

Reasons to Add Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.

HealthEquity (HQY) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.